• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乳腺癌患者的瘤外乳腺组织:一项针对低风险和高风险国家中年龄及居住国差异的多国研究。世界卫生组织肿瘤与甾体避孕药协作研究。

Extratumoral breast tissue in breast cancer patients: a multinational study of variations with age and country of residence in low- and high-risk countries. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.

作者信息

Aaman T B, Stalsberg H, Thomas D B

机构信息

Institute of Medical Biology, University of Tromso, Norway.

出版信息

Int J Cancer. 1997 May 2;71(3):333-9. doi: 10.1002/(sici)1097-0215(19970502)71:3<333::aid-ijc4>3.0.co;2-z.

DOI:10.1002/(sici)1097-0215(19970502)71:3<333::aid-ijc4>3.0.co;2-z
PMID:9139863
Abstract

With the aim of elucidating the relationships between breast cancer, risk factors and benign breast changes, extratumoral breast tissue in 1,506 women from the WHO Collaborative study of neoplasia and steroid contraceptives was studied histologically. Patients came from 3 countries with a high incidence of breast cancer (Israel, East Germany and Australia) and 6 low-risk countries (Thailand, China, Philippines, Mexico, Chile and Colombia). Ductal atypia, ductal hyperplasia, adenosis, lobular atypia, apocrine metaplasia, apocrine hyperplasia, apocrine atypia, cysts, duct ectasia, inflammatory reaction, calcification, lactational change and epithelial-stromal ratio were classified as absent/mild/moderate/marked. Prevalence odds ratios were calculated by logistic regression analyses. Increasing frequency with age was found for ductal hyperplasia, sclerosing adenosis, apocrine metaplasia and cysts, while adenosis, lactational change and the epithelial-stromal ratio decreased with age. No significant difference between high- and low-risk countries was found for ductal hyperplasia or sclerosing adenosis. Compared with cases from high-risk countries, those from low-risk countries had a significantly lower prevalence of apocrine metaplasia, apocrine hyperplasia and cysts, and a significantly higher prevalence of ductal atypia. When seen in conjunction with other studies, the results suggest that ductal hyperplasia and sclerosing adenosis have similar roles in cancer development in high- and low-risk countries and that the factors responsible for international differences in breast cancer may exert their effect by influencing the initial development of these changes. They also suggest a delayed progression from noninvasive to invasive carcinoma in low-risk countries.

摘要

为了阐明乳腺癌、危险因素与乳腺良性病变之间的关系,对来自世界卫生组织肿瘤与甾体避孕药协作研究的1506名女性的瘤外乳腺组织进行了组织学研究。患者来自3个乳腺癌高发国家(以色列、东德和澳大利亚)和6个低风险国家(泰国、中国、菲律宾、墨西哥、智利和哥伦比亚)。将导管异型增生、导管增生、腺病、小叶异型增生、大汗腺化生、大汗腺增生、大汗腺异型增生、囊肿、导管扩张、炎症反应、钙化、哺乳期改变及上皮-间质比例分为无/轻度/中度/重度。通过逻辑回归分析计算患病率比值比。发现导管增生、硬化性腺病、大汗腺化生和囊肿的发生率随年龄增加,而腺病、哺乳期改变及上皮-间质比例随年龄下降。导管增生或硬化性腺病在高风险国家和低风险国家之间未发现显著差异。与高风险国家的病例相比,低风险国家的病例大汗腺化生、大汗腺增生和囊肿的患病率显著较低,而导管异型增生的患病率显著较高。结合其他研究来看,结果表明导管增生和硬化性腺病在高风险国家和低风险国家的癌症发展中具有相似作用,并且导致乳腺癌国际差异的因素可能通过影响这些改变的初始发展发挥作用。结果还提示低风险国家从非浸润性癌向浸润性癌的进展延迟。

相似文献

1
Extratumoral breast tissue in breast cancer patients: a multinational study of variations with age and country of residence in low- and high-risk countries. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.乳腺癌患者的瘤外乳腺组织:一项针对低风险和高风险国家中年龄及居住国差异的多国研究。世界卫生组织肿瘤与甾体避孕药协作研究。
Int J Cancer. 1997 May 2;71(3):333-9. doi: 10.1002/(sici)1097-0215(19970502)71:3<333::aid-ijc4>3.0.co;2-z.
2
Extra-tumoral breast tissue in breast-cancer patients: variations with a family history of breast cancer. WHO Collaborative Study of Neoplasia and Steroid Contraceptives.乳腺癌患者的肿瘤外乳腺组织:有乳腺癌家族史者的差异。世界卫生组织肿瘤与甾体避孕药协作研究。
Int J Cancer. 1998 Feb 20;79(1):39-43. doi: 10.1002/(sici)1097-0215(19980220)79:1<39::aid-ijc8>3.0.co;2-x.
3
Extra-tumoral breast tissue in breast cancer patients: variations with steroid contraceptive use.乳腺癌患者的肿瘤外乳腺组织:使用甾体类避孕药的差异
Int J Cancer. 2006 Jun 1;118(11):2827-31. doi: 10.1002/ijc.21697.
4
Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.大汗腺化生型硬化性腺病中乳腺癌前病变及肌上皮增生的特征分析
Mol Oncol. 2007 Jun;1(1):97-119. doi: 10.1016/j.molonc.2007.02.005. Epub 2007 Mar 14.
5
Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study.不同乳腺癌风险人群中良性、非典型和恶性乳腺病变的患病率。一项法医尸检研究。
Cancer. 1987 Dec 1;60(11):2751-60. doi: 10.1002/1097-0142(19871201)60:11<2751::aid-cncr2820601127>3.0.co;2-m.
6
The Histologic Spectrum of Apocrine Lesions of the Breast.乳腺顶泌汗腺病变的组织学谱
Am J Clin Pathol. 2000 May;113(suppl_1):S3-18. doi: 10.1309/7A2P-YMWJ-B1PD-UDN9.
7
Fibroadenoma of the breast: analysis of associated pathological entities--a different risk marker in different age groups for concurrent breast cancer.乳腺纤维腺瘤:相关病理实体分析——不同年龄组并发乳腺癌的不同风险标志物
Isr Med Assoc J. 2001 Nov;3(11):813-7.
8
Loss of heterozygosity in fibrocystic change of the breast: genetic relationship between benign proliferative lesions and associated carcinomas.乳腺纤维囊性变中的杂合性缺失:良性增生性病变与相关癌之间的遗传关系。
Am J Pathol. 2000 Jul;157(1):323-9. doi: 10.1016/S0002-9440(10)64543-9.
9
Atypical apocrine adenosis of the breast: a clinicopathologic study of 37 patients with 8.7-year follow-up.乳腺非典型大汗腺腺病:37例患者的临床病理研究及8.7年随访
Cancer. 1996 Jun 15;77(12):2529-37. doi: 10.1002/(SICI)1097-0142(19960615)77:12<2529::AID-CNCR16>3.0.CO;2-U.
10
A pathologic study of benign breast diseases in Tokyo and New York.
Cancer. 1982 Nov 1;50(9):1899-903. doi: 10.1002/1097-0142(19821101)50:9<1899::aid-cncr2820500942>3.0.co;2-a.

引用本文的文献

1
Benign Breast Disease, NSAIDs, and Postmenopausal Breast Cancer Risk in the CPS-II Cohort.良性乳腺疾病、非甾体抗炎药与 CPS-II 队列中老年后乳腺癌风险。
Cancer Prev Res (Phila). 2023 Mar 1;16(3):175-184. doi: 10.1158/1940-6207.CAPR-22-0403.
2
Plasma equol concentration is not associated with breast cancer and fibrocystic breast conditions among women in Shanghai, China.在中国上海女性中,血浆雌马酚浓度与乳腺癌及乳腺纤维囊性病变无关。
Nutr Res. 2016 Aug;36(8):863-71. doi: 10.1016/j.nutres.2016.03.008. Epub 2016 Mar 30.
3
A review of breast cancer care and outcomes in Latin America.
拉丁美洲乳腺癌诊治与结局的研究综述。
Oncologist. 2013;18(3):248-56. doi: 10.1634/theoncologist.2012-0373. Epub 2013 Feb 26.
4
Selected estrogen receptor 1 and androgen receptor gene polymorphisms in relation to risk of breast cancer and fibrocystic breast conditions among Chinese women.中国女性中雌激素受体 1 和雄激素受体基因多态性与乳腺癌和乳腺纤维囊性病变风险的关系。
Cancer Epidemiol. 2011 Feb;35(1):48-55. doi: 10.1016/j.canep.2010.08.005. Epub 2010 Sep 17.
5
Dietary and stored iron as predictors of breast cancer risk: A nested case-control study in Shanghai.膳食铁与储存铁作为乳腺癌风险的预测因素:上海的一项巢式病例对照研究。
Int J Cancer. 2009 Sep 1;125(5):1110-7. doi: 10.1002/ijc.24404.
6
Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.中国上海女性中CYP19A1基因变异与乳腺癌及乳腺纤维囊性病变风险
Cancer Epidemiol Biomarkers Prev. 2008 Dec;17(12):3457-66. doi: 10.1158/1055-9965.EPI-08-0517.
7
Erythrocyte fatty acids and risk of proliferative and nonproliferative fibrocystic disease in women in Shanghai, China.中国上海女性红细胞脂肪酸与增殖性和非增殖性纤维囊性疾病风险
Am J Clin Nutr. 2009 Jan;89(1):265-76. doi: 10.3945/ajcn.2008.26077. Epub 2008 Dec 3.
8
Polymorphisms in steroid hormone biosynthesis genes and risk of breast cancer and fibrocystic breast conditions in Chinese women.中国女性甾体激素生物合成基因多态性与乳腺癌及乳腺纤维囊性病变风险
Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1066-73. doi: 10.1158/1055-9965.EPI-07-2680.
9
Glutathione S-transferase M1 and P1 polymorphisms and risk of breast cancer and fibrocystic breast conditions in Chinese women.谷胱甘肽S-转移酶M1和P1基因多态性与中国女性患乳腺癌及乳腺纤维囊性病变的风险
Breast Cancer Res Treat. 2008 May;109(1):143-55. doi: 10.1007/s10549-007-9633-5. Epub 2007 Jul 12.
10
Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer.结肠癌旁增生性结肠黏膜诱导血管生成。
Am J Pathol. 2000 Nov;157(5):1523-35. doi: 10.1016/S0002-9440(10)64790-6.